ADC Therapeutics Q2 2026 Earnings: Lower Spending Narrows the Loss
ADC Therapeutics (ADCT) reported a narrowed GAAP loss per share in Q2 2026, reaching $0.11, primarily due to a significant 29% reduction in operating expenses, despite only a modest 2% increase in total revenue to $19.2 million. However, the company faces material regulatory uncertainty …